The escalation ends and the weight settles, and a reasonable expectation is that the bill settles too. It does, at whatever the top of the ladder turned out to be — which is a different statement from the one most pricing pages invite. The reason is that “maintenance” is a word from a prescribing label before it is a word on a price list, and the label does not use it to mean one dose. How the climb gets there is the schedule article; what happens when it stops is here.
The approved maintenance dose is a range
The semaglutide label lists 1.7 mg, 2.4 mg and 7.2 mg as maintenance options once weekly — a span of 4.2 times from lowest to highest. The tirzepatide label lists 5 mg, 10 mg and 15 mg, a span of three, and it says outright that its 2.5 mg step is for treatment initiation and is not approved as a maintenance dosage. Its 7.5 mg and 12.5 mg steps appear in no maintenance list at all; they exist because escalation moves in 2.5 mg increments.
Two people can therefore both be at a labeled maintenance dose and be three times apart in milligrams. Wherever a seller indexes price to milligrams, that span stops being a clinical fact and becomes a billing one.
What the span is worth on a real price list
Among the 477 sellers recorded here, one publishes a ladder whose rungs step in the same milligrams the approved schedule uses. It prices the three approved tirzepatide maintenance doses at $295 at 5 mg, $395 at 10 mg and $545 at 15 mg per four-week fill. The top approved option is 1.85 times the lowest.
Thirteen four-week fills land in a calendar year, so those three doses cost $3,835, $5,135 and $7,085 a year. A $3,250 spread sits inside one word, and nothing on a comparison surface distinguishes the buyers at either end. Running a specific milligram and a specific rung through the cost calculator is the only way that spread becomes visible before the fourth month.
The newest maintenance option is priced in one channel only
Semaglutide’s 7.2 mg maintenance option is the recent addition, and it barely exists on a price list. Searching every price row and every seller write-up here for a figure attached to that strength returns nothing from the compounded field at all; the only 7.2 mg prices recorded are from two branded channels, at $399 a month against $349 for every pen strength from 0.25 mg to 2.4 mg.
So the top of the approved semaglutide range costs a stated $50 a month more than the rest of it where anyone prices it, and is unpriced everywhere else. A compounding pharmacy is not obliged to follow an approved ladder and may prepare any strength a prescriber writes, which means a buyer asking for that dose on a cash plan is asking for something outside every published figure on both sides of the market.
A held rate protects the climb and penalizes the descent
148 of those 477 sellers state that one price covers every dose, 36 state that it rises with the dose, and 293 state nothing either way. Through escalation the first group is plainly the better deal, which is why a board of held rates exists and why the arithmetic of the climb favors it, as worked through in the second-year article.
At the plateau it inverts. A patient who settles at 5 mg rather than 15 mg, or who steps back down after reaching a goal weight, recovers $250 a fill and $3,250 a year from the dose-indexed seller and nothing from the flat one. A held rate is insurance against the climb, and insurance is not free; the premium is collected from everyone who ends up maintaining below the top of the ladder.
What a seller means by a maintenance tier
Of the 220 sellers written up here, four name a maintenance tier as a distinct product and three attach a price to it. The fourth bundles a dietitian-led maintenance program into the plan without a separate figure.
Two of the three price it below the standing rate. One sells a semaglutide plan at $149.99 covering every dose from 0.25 mg to 2.5 mg, and a maintenance program at $139.99 — 6.7% less — limited to 0.25 mg; the same seller runs a $249.99 tirzepatide rate covering 2 mg to 15 mg against a $179.99 maintenance program, 28.0% less, limited to 2 mg. The other prices a “microdose and maintain” track at $219 against $259 for its full-dose track, 15.4% less.
Here is what those discounts are buying. Semaglutide at 0.25 mg is the label’s initiation dose, the step a schedule spends four weeks on so the gut can adjust; tirzepatide at 2 mg sits below the 5 mg floor of the approved maintenance list and below the 2.5 mg initiation step. The cheaper maintenance tier is cheaper because it is dosed under anything the labels call maintenance, and the vocabulary that makes that sound ordinary is examined in the microdose article.
The same word, used for the opposite thing
The third seller uses “maintenance” to mean the standing rate that begins once a required discounted opening order runs out. Its introductory two-month semaglutide order works out at $49.50 a month; its maintenance rate is $216 a calendar month, 4.36 times the opening figure. On tirzepatide the same structure runs $174.50 against $379, a multiple of 2.17.
So one word marks a discount at two sellers and the end of a discount at a third. A reader who has learned that a maintenance tier is the cheap one will misread the third page badly, and neither usage is wrong on its own terms. Both are simply names a business chose, sitting next to a clinical term that means something else again.
A flat rate is only checkable if a milligram is printed
“One price at every dose” is a promise about a range, and a range with no endpoints cannot be tested. Of the 220 sellers written up here, the question of whether any milligram strength appears beside a price was settled for 130. Of those, 39 publish a dose and 91 do not — so on the sellers where it was checked, roughly three in ten make their own flat-rate claim verifiable.
The difference shows up at exactly the moment this page is about. A seller stating that $149.99 covers 0.25 mg through 2.5 mg has committed to a ceiling; a seller stating that one price covers every dose, with no strength printed anywhere, has committed to a sentence. The second is not necessarily worse behaved. It is simply not answerable until an intake is finished and a card is on file.
Whether a lower maintenance dose is a worse one
A capped tier is easy to dismiss and the evidence does not support dismissing it. A multicenter prospective cohort of 112 non-diabetic Japanese adults compared tirzepatide maintained at 2.5 mg (n=58) against escalation to 5 mg (n=54) after four weeks, with the choice made by shared decision rather than randomization. At six months the primary outcome was reached by 62.1% and 63.0% respectively (HR 0.93; 95% CI, 0.58 to 1.49; p = 0.772), with mean weight loss of −15.3% and −16.1% (p = 0.563) and adverse events in 35% against 50%.[1]
A much larger real-world series points the same way. Among 630,545 adults initiating tirzepatide for obesity through a United Kingdom digital prescribing service, 89.9% had lost at least 5% of body weight at six months and 72.1% at least 10%, and the authors report that clinically meaningful outcomes were frequently achieved without escalation beyond intermediate doses, concluding that maximal dose escalation was often unnecessary.[2] Every author of that paper was employed during the study by the company operating the service, which sells both molecules — a conflict the paper discloses and that belongs beside the finding.
Neither study is a randomized comparison of holding a dose against reducing it, and nobody has run one. The first was non-randomized and small, in a population whose baseline body-mass index averaged 30.8. The second measured self-reported weights inside a commercial service. What they establish is that the question is open, not that the cheaper tier is equivalent — and a plateau that arrives early has its own explanations, gathered in the plateau article.
What this does not establish
Coverage is not census. 293 of the 477 sellers here state no dose-pricing policy at all, and most have not been individually adjudicated on it. A seller with no maintenance tier in its write-up has not been examined and found to hold one rate forever; it has not been examined. The three priced tiers above are the sellers who published enough to be read.
Nor does a price describe the preparation. Compounded drugs are not FDA-approved, which means the agency does not verify their safety, effectiveness or quality before they are marketed, and a compounding pharmacy is free to dispense a ladder no label contains.[3] A maintenance dose chosen because it is the one a plan covers is a clinical decision made by a billing department, and the answer to that is a prescriber rather than a cheaper tier. How a figure gets established before it is published here is set out in the methodology.